For example, dual GIP/GLP-1 receptor agonists such as tirzepatide have received regulatory approval for metabolic indications, expanding the clinical toolbox
Weeks 1-4 Starting dose Weeks 5-8 First increase Weeks 9-12 Therapeutic level Weeks 13-16 Near target Week 17+ Full dose Side Effects & Safety Most side effects are mild, temporary, and occur during dose increases
SSTR2a significantly increased mean glucagon output at low glucose ( P = 0.005), and a significant, albeit minor, increase was observed at high glucose ( P = 0.04) (Figure 2F)
Kate Knibbs: I would also love to know that
Whats included in my plan
What to eat (and what to avoid) to minimize side effects like nausea, fatigue, and digestive issues